Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Operationalizing Precision Medicine in Rare Disease Trials Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research Opening Keynote: The Future of Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development
Commercialization, • 9/19/25 What Matters to Payers: Conversations You Should Start During Phase 2 Previous Designing Trials with the End in Mind: Building Market Access into Rare Disease Clinical Development Next Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories You Might Also Like Operationalizing Precision Medicine in Rare Disease Trials Real-World Evidence That Matters: A Hands-On Workshop in Building Credible Value Stories Ethics and Strategies for Returning Individual Patient Data Collected in Clinical Research Opening Keynote: The Future of Rare Disease Trials Accelerating Rare Disease Therapies: Strategies for Efficient Clinical Development
